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j.ajkd.2019.05.018Rationale & Objective: Studies of patients on
maintenance dialysis therapy suggest that
standard-dose influenza vaccine (SDV) may not
prevent influenza-related outcomes. Little is
known about the comparative effectiveness of
SDV versus high-dose influenza vaccine (HDV)
in this population.
Study Design: Cohort study using data from the
US Renal Data System.
Setting & Participants: 507,552 adults under-
going in-center maintenance hemodialysis
between the 2010 to 2011 and 2014 to 2015
influenza seasons.
Exposures: SDV and HDV.
Outcomes: All-cause mortality, hospitalization
due to influenza or pneumonia, and influenza-like
illness during the influenza season.
Analytic Approach: Patients were eligible for in-
clusion in multiple yearly cohorts; thus, our unit of
analysis was the influenza patient-season. To
examine the relationship between vaccine dose
and effectiveness outcomes, we estimated risk
differences and risk ratios using propensity
score weighting of Kaplan-Meier functions,
accounting for a wide range of patient- and
facility-level characteristics. For nonmortality
outcomes, we used competing-risk methods toaccount for the high mortality rate in the dialysis
population.
Results: Within 225,215 influenza patient-
seasons among adults 65 years and older,
97.4% received SDV and 2.6% received HDV.
We observed similar risk estimates for HDV and
SDV recipients for mortality (risk
difference, −0.08%; 95% CI, −0.85% to
0.80%), hospitalization due to influenza or
pneumonia (risk difference, 0.15%; 95%
CI, −0.69% to 0.93%), and influenza-like illness
(risk difference, 0.00%; 95% CI, −1.50% to
1.08%). Our findings were similar among adults
younger than 65 years, as well as within other
subgroups defined by influenza season, age
group, dialysis vintage, month of influenza
vaccination, and vaccine valence.
Limitations: Residual confounding and outcome
misclassification.
Conclusions: The HDV does not appear to
provide additional protection beyond the SDV
against all-cause mortality or influenza-related
outcomes for adults undergoing hemodialysis.
The additional cost and side effects
associated with HDV should be considered
when offering this vaccine. Future studies of
HDV and other influenza vaccine strategies
are warranted.Influenza causes substantial morbidity and mortality inpatients with end-stage renal disease (ESRD). Patients
with ESRD have an impaired innate and adaptive immune
system, including defects in complement activation and B-
and T-cell function,1-3 which contribute to increased risks
for severe complications from influenza or influenza-
related hospitalizations, mortality, and health care costs
compared to the general population.4-7 The Centers for
Disease Control and Prevention (CDC) has long recom-
mended that patients with ESRD receive annual influenza
vaccinations.8,9
Currently, several types of influenza vaccines are avail-
able in the United States, including the standard-dose
(SDV) and high-dose influenza vaccines (HDV). The tri-
valent—and more recently quadrivalent—inactivated sea-
sonal SDVs have been administered as standard practice in
dialysis clinics. In 2009, the US Food and Drug Adminis-
tration licensed a trivalent HDV for use among adults 65
years and older to induce higher antibody responses andprovide better protection from influenza than the SDV.10
The HDV contains the same 3 strains as SDV but more
antigen (60 vs 15 μg per strain) than standard vaccines.
Use of the HDV among patients on maintenance hemo-
dialysis has increased slowly over time.11
An accumulating body of literature demonstrates that the
HDV is more effective than SDVs in preventing influenza-
related medical encounters, hospitalizations, and mortality
in the general population of adults 65 years and older.12-18
However, some studies of healthy older adults have not
demonstrated a benefit of HDV.19,20 In the dialysis popula-
tion, a recent observational study by Miskulin et al21 reported
that HDVwas more effective than SDV in preventing all-cause
hospitalization during the 2016 to 2017 influenza season,
but not the 2015 to 2016 season. However, this study was
limited by small sample size, adjustment for a small set of
potential confounders, and the absence of influenza-related
outcomes, warranting additional examination of the effec-
tiveness of the HDV in the dialysis population.
We sought to compare the clinical effectiveness of HDV
versus SDV in preventing all-cause mortality, hospitaliza-
tion due to influenza or pneumonia, and influenza-like
illness (ILI) among patients with chronic kidney failure
undergoing maintenance hemodialysis. Because the
healthy-user effect and frailty are well-documented chal-
lenges of observational studies of influenza vaccine effec-
tiveness in populations with poor health, we used robust
methods to account for possible confounding. We also
used competing-risk methods to account for the high
mortality rate in the dialysis population.Methods
Data Source
We used the US Renal Data System (USRDS) to identify
patients with chronic kidney disease receiving in-center
maintenance hemodialysis during 2009 to 2015. USRDS
is a national registry of patients with ESRD who are eligible
for Medicare coverage from the Centers for Medicare &
Medicaid Services (CMS), and it contains routinely re-
ported clinical information from dialysis centers, as well as
Medicare claims for inpatient, outpatient, and physician
diagnoses and procedures.22
Study Design and Patients
We constructed yearly cohorts for 5 individual influenza
seasons: 2010 to 2011, 2011 to 2012, 2012 to 2013,
2013 to 2014, and 2014 to 2015. The index dates were
anchored on the date of influenza vaccination (Fig 1),
which was required to be administered before the start
date of the influenza season. Eligible patients included
adults 18 years or older with ESRD and Medicare as a
primary insurance payer who had started hemodialysis at
least 9 months before the index date, to allow for a 3-
month Medicare enrollment period before the 6-month
baseline period. We further required continuous hemo-
dialysis receipt for the 3 months immediately before
vaccination. Baseline covariates were ascertained during
the 6-month baseline period before the index date. The






Figure 1. Study design schematic of inclusion criteria and follow-u
tenance hemodialysis. The index date was anchored on the date o
before the start date of the influenza season. Follow-up began onseason. The start and end dates of each influenza season
were defined using national influenza surveillance data
from the CDC.23-27 Specifically, the start and end of each
season were defined as the midpoint of the first week
during which >10% and <10%, respectively, of national
culture isolates were positive for influenza (Table S1). The
primary analysis was conducted in adults 65 years and
older; a secondary analysis was conducted in adults
younger than 65 years. Patients could be eligible for in-
clusion in multiple yearly cohorts.
Exposure Assessment
Influenza vaccines were classified as HDV, SDV, or un-
known (Table S2), based on outpatient, physician, and
inpatient procedure coding in billing claims for influenza
vaccine or influenza vaccine administration. We searched
for Current Procedural Terminology, Healthcare Common Procedure
Coding System (HCPCS), and International Classification of Diseases,
Ninth Revision, Clinical Modification (ICD-9-CM) codes assigned
between August 1 and the end of each influenza season.
We assumed that multiple codes within a 7-day period
were duplicate codes for the same vaccination and there-
fore 2 codes for the same vaccine dose were collapsed,
whereas 2 codes for a known and unknown dose were
categorized as the known dose. Codes within 7 days for
different known doses were considered separate doses.
Codes spaced by greater than 7 days were also considered
separate doses.
Outcome Assessment
We examined 3 primary clinical outcomes: all-cause
mortality, the first occurrence of hospitalization for
influenza or pneumonia, and the first occurrence of ILI.
All-cause mortality was assessed using the CMS ESRD Death
Notification Form. Because laboratory-confirmed influenza
status is not available in the claims data, we used 2 levels of
claims-based influenza definitions from diagnosis coding:
(1) hospitalization for influenza or pneumonia and (2)
inpatient or outpatient ILI (see Table S3 for code lists). We
performed sensitivity analysis of ILI with a narrower
definition, as done previously.28,29ths 
alysis
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p time for each yearly cohort of adult patients undergoing main-
f influenza vaccination, which was required to be administered
the start date of the influenza season.
Table 1. Characteristics of the 225,215 Unique Influenza Patient-
Seasons Among US Adults 65 Years and Older Undergoing
Maintenance Hemodialysis, by Influenza Vaccine Dose
Characteristic
HDV
(n = 5,776; 2.6%)
SDV
(n = 219,439; 97.4%)
Mean age, y 75.8 ± 6.9 74.6 ± 7.0
Male sex 3,064 (53.0%) 111,827 (51.0%)
Race
White 4,378 (75.8%) 134,917 (61.5%)
Black 1,125 (19.5%) 71,408 (32.5%)
Other 273 (4.7%) 13,114 (6.0%)
Cause of ESRD
Diabetes 2,524 (43.7%) 103,702 (47.3%)
Hypertension 1,898 (32.9%) 71,973 (32.8%)
GN 443 (7.7%) 14,708 (6.7%)
Other 911 (15.8%) 29,056 (13.2%)
Region
Northeast 928 (16.1%) 37,869 (17.3%)
South 1,959 (33.9%) 97,158 (44.3%)
West 801 (13.9%) 39,280 (17.9%)
Midwest 2,088 (36.1%) 45,132 (20.6%)
Dual-eligible for
Medicaid
1,338 (23.2%) 76,492 (34.9%)
Dialysis vintage
<1 y 420 (7.3%) 11,394 (5.2%)
1-2 y 2,512 (43.5%) 76,237 (34.7%)
3-4 y 1,348 (23.3%) 54,441 (24.8%)
5-9 y 1,172 (20.3%) 58,560 (26.7%)




0 5,391 (93.3%) 205,549 (93.7%)
1-6 257 (4.4%) 9,358 (4.3%)
≥7 128 (2.2%) 4,532 (2.1%)
Skilled nursing facility
in last mo
133 (2.3%) 5,911 (2.7%)
Comorbid conditions
Cancer 895 (15.5%) 25,393 (11.6%)
COPD 898 (15.5%) 29,177 (13.3%)
Diabetes 3,666 (63.5%) 141,026 (64.3%)
Hypertension 3,896 (67.5%) 139,110 (63.4%)
Ischemic heart
disease
3,613 (62.6%) 122,555 (55.8%)




1,328 (23.0%) 55,171 (25.1%)
Difficulty walking 714 (12.4%) 28,605 (13.0%)
Mobility aidsa 526 (9.1%) 22,011 (10.0%)
Skin ulcer
(decubitus)
575 (10.0%) 19,792 (9.0%)
Use of oxygen 664 (11.5%) 22,370 (10.2%)
Weakness 632 (10.9%) 26,796 (12.2%)
(Continued)
Table 1 (Cont'd). Characteristics of the 225,215 Unique Influ-
enza Patient-Seasons Among US Adults 65 Years and Older
Undergoing Maintenance Hemodialysis, by Influenza Vaccine Dose
Characteristic
HDV
(n = 5,776; 2.6%)
SDV
(n = 219,439; 97.4%)
Screening tests/
prevention
HbA1c test 3,155 (54.6%) 129,109 (58.8%)
Cancer screening 841 (14.6%) 30,543 (13.9%)
Diabetic eye
examination
2,177 (37.7%) 71,798 (32.7%)
Hepatitis B vaccine/
titer
1,288 (22.3%) 42,217 (19.2%)
Lipid test 1,991 (34.5%) 66,996 (30.5%)
Pneumococcal
vaccine
321 (5.6%) 10,974 (5.0%)
Abbreviations: COPD, chronic obstructive pulmonary disease; ESRD, end-stage
renal disease; GN, glomerulonephritis; HbA1c, hemoglobin A1c; HDV, high-dose
vaccine; SDV, standard-dose vaccine.
aDefined as use of walker, wheelchair, or modified bathroom equipment.Covariates
Our analyses included a wide range of covariates identified
during the 6-month baseline period (Fig 1; Table S4).
Covariates included demographic characteristics (eg, age,sex, race, dual-eligible for Medicaid, region, and year),
clinical characteristics (eg, cause of ESRD and years on
dialysis), dialysis facility characteristics (eg, affiliation,
type, profit status, and size), and several comorbid con-
ditions and procedures captured using ICD-9-CM and
HCPCS codes. To account for potential confounding by
frailty30,31 and healthy-user bias,32,33 we also included
covariates on preventive health services (eg, other vacci-
nations and health screenings), health care utilization (eg,
skilled nursing days and hospital days), and frailty in-
dicators (eg, oxygen use and mobility aids). We catego-
rized the timing of vaccine administration as vaccination in
August or September versus October through the start of
influenza season.Statistical Analysis
Patients could be eligible for inclusion in multiple yearly
cohorts; thus, our unit of analysis was the influenza
patient-season. To examine the relationship between vac-
cine dose and effectiveness outcomes, we estimated crude
and weighted cumulative risk functions using Kaplan-
Meier methods, accounting for the competing risk for
death (for the nonmortality outcomes of ILI and hospi-
talization due to influenza or pneumonia).34-36 We
addressed potential confounding due to differences in
observed covariates between HDV and SDV recipients by
using propensity score weighting methods. Specifically,
we applied standardized mortality ratio weights to the
Kaplan-Meier estimator. We estimated the predicted
probability of receiving HDV, or the propensity score (ps),
using logistic regression with a priori selected potential
confounders as predictors (Table S4). Age was modeled
using restricted quadratic splines with 4 knots. Standard-
ized mortality ratio weights for SDV recipients were
calculated as ps/(1 − ps); HDV recipients remained un-
































































































































































































































































































































































































































































































































































































































































































































































e.of baseline covariates in the unweighted and standardized
mortality ratio–weighted populations to determine
whether weighting the population reduced imbalances of
observed covariates and made the treatment groups more
exchangeable.38 We stratified models by influenza season,
valence, age, dialysis vintage (in years), and timing of
influenza vaccination; weights were created separately for
each subgroup analysis. Covariate balance was assessed
separately for each subgroup analysis. Patients receiving
influenza vaccine before the beginning of the influenza
season were followed up from the first day of the influenza
season until the first occurrence of the outcome, a
competing-risk event (ie, death for nonmortality out-
comes), or a censoring event (ie, disenrollment from
Medicare Parts A and B, kidney transplantation, switch to
peritoneal dialysis, loss to follow-up, receipt of a subse-
quent influenza vaccine, or end of influenza season). We
calculated risk differences and risk ratios using the cu-
mulative risk function estimates at the end of each influ-
enza season. A nonparametric-based bootstrap was used to
estimate 95% confidence intervals (CIs) for daily risk dif-
ferences and risk ratios between groups. Additionally, we
conducted bias analyses to estimate the strength of un-
measured confounders that would be required to mask
associations between vaccine type and each primary
outcome after adjusting for measured covariates.39
This study using deidentified data was considered
exempt from human subject review by the Institutional
Review Board at Washington University. Analyses were
performed using SAS, version 9.4 (SAS Institute), and R
Statistical Software, version 3.3.40Results
After applying inclusion and exclusion criteria, we iden-
tified 255,281 eligible adult patients who contributed
507,552 unique influenza patient-seasons (Fig S1). In the
primary analysis of adults 65 years and older (n = 225,215
influenza patient-seasons), SDV made up 97.4%
(n = 219,439) of the eligible vaccinations, and HDV was
administered in the remaining 2.6% (n = 5,776). All HDV
were trivalent, whereas 76.7% of SDV were trivalent and
23.3% were quadrivalent.
Tables 1 and S5 present characteristics of the study
population stratified by vaccine dose. Mean age was
slightly older among HDV recipients than SDV recipients
(75.8 vs 74.6 years). HDV administration was less com-
mon among patients who were black or other race, dual-
eligible for Medicaid, on dialysis for 3 or more years, or
residing outside of the Midwest. HDV recipients had a
higher prevalence of several comorbid conditions,
including ischemic heart disease, chronic obstructive pul-
monary disease, cancer, and liver disease. HDV and SDV
recipients had a similar prevalence of frailty indicators.
HDV recipients were more likely to receive preventive
health care such as diabetic eye examinations, lipid testing,
and cancer screenings. Some characteristics of the HDV
recipients changed over time (eg, dialysis vintage;
Table S6). The distribution of observed covariates was well
balanced after propensity score weighting, as indicated by
standardized mean differences <10% in the weighted
population.41 Figure S2 presents these results for the pri-
mary analysis.
The counts of outcome events, censoring events,
competing-risk events, and person-time at risk are pre-
sented for each outcome in Table 2. Among SDV re-
cipients, crude risks for death and hospitalization for
pneumonia or influenza were similar (8.7% and 7.6%,
respectively); in contrast, the risk for ILI was more than 3
times higher (28.1%).
For each outcome, we observed similar weighted risks
for HDV and SDV recipients throughout the influenza sea-
son, accounting for the competing risk for death for non-
mortality outcomes (Fig 2). In the weighted analyses, we
observed similar associations between vaccine dose and risk
for mortality (risk difference, −0.08%; 95% CI, −0.85% to
0.80%), hospitalization due to influenza or pneumonia (risk
difference, 0.15%; 95% CI, −0.69% to 0.93%), and ILI (risk
difference, 0.00%; 95% CI, −1.50% to 1.08%).
Results did not change appreciably in the analysis with
the restricted ILI definition (Table S7). Estimates on the
relative scale followed similar patterns (Table 2).
Within subgroups, risks for mortality, hospitalization
for pneumonia or influenza, and ILI were generally similar
between HDV and SDV recipients throughout the influenza






























Figure 2. Cumulative risk and 95% confidence interval estimate
influenza-like illness, accounting for the competing risk for death (
(2010/2011, 2011/2012, 2012/2013, 2013/2014, 2014/2015)
ratio–weighted Kaplan-Meier functions. The scales of the y-axes diff
SDV, standard-dose influenza vaccine.Tables S8-S10). First, we observed higher risk for hospi-
talization among HDV versus SDV recipients in the 2010 to
1011 season (risk difference, 2.85%; 95% CI, 0.59%-
5.86%), but not for any other season. Also, for both the
hospitalization and ILI outcomes, we observed higher risk
among HDV versus SDV recipients who were aged 65 to
74 years, lower risk among those aged 75 to 84 years, and
no difference in risk between those younger than 65 or 85
years and older.
In the bias analyses, we quantified the possibility that
our observed null associations may be explained by an
unmeasured confounding variable. We observed that the
exposure–confounder relative risk and the confounder-
outcome relative risk must have been at least as large as
1.4, 1.5, and 1.3 for mortality, hospitalization due to
influenza or pneumonia, and ILI, respectively, to have
shifted the corresponding weighted upper confidence limit
across the null (Tables S11-S13).Discussion
We conducted a large comparative study of the effective-
ness of the HDV versus SDV among adults with chronic
kidney failure undergoing maintenance hemodialysis in
the United States. In the overall population, we observed
similar risks for all-cause mortality, hospitalization due to
influenza or pneumonia, and ILI among patients who
received HDV compared with those who received SDV.
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for nonmortality outcomes), pooled across 5 influenza seasons 
. Cumulative risk was estimated using standardized mortality 
er by outcome. Abbreviations: HDV, high-dose influenza vaccine; 
Subgroup Risk Difference, % (95% CI)SDV vs. HDV (N)
Age (years)
<65  0.88 (-0.39,  2.32)281,203 vs. 1,134
65-74 -0.17 (-1.18,  0.79)118,624 vs. 2,674
75-84 0.57 (-0.78,  1.84)78,011 vs. 2,375
>=85 -1.38 (-3.79,  1.19)22,804 vs. 727
Influenza season
2010/11 -0.80 (-4.05,  1.80)42,607 vs. 368
2011/12 -0.47 (-2.07,  1.39)35,936 vs. 748
2012/13 -0.25 (-2.03,  1.27)48,346 vs. 1,165
2013/14 -0.37 (-1.68,  1.10)44,413 vs. 1,447
2014/15 0.57 (-0.71,  1.82)48,137 vs. 2,048
Years with ESRD
<1 year -0.87 (-4.09,  1.81)11,394 vs. 420
1-2 years 0.90 (-0.20,  2.26)76,237 vs. 2,512
3-4 years -0.50 (-1.97,  1.42)54,441 vs. 1,348
5-9 years -1.97 (-3.58,  0.09)58,560 vs. 1,172
>=10 years 1.51 (-2.46,  5.32)18,807 vs. 324
Timing of vaccination
August / September -0.68 (-1.59,  0.52)130,035 vs. 3,124
October or later 0.61 (-0.54,  1.79)89,404 vs. 2,652
Valence of SDV
Trivalent -0.08 (-0.73,  0.92)168,288 vs. 5,776
Quadrivalent -0.48 (-1.38,  0.51)51,151 vs. 5,776
-6 -4 -2 0 2 4 6
Figure 3. The risk for mortality among patients who received the high-dose (HDV) versus standard-dose (SDV) influenza vaccine, by 
subgroup. Risk differences were calculated as the difference between weighted cumulative risk functions, with bootstrap confidence 
intervals (CIs). Analyses were performed in adults 65 years and older, with the exception of the age-stratified analyses. Abbreviation: 
ESRD, end-stage renal disease.influenza season, age group, years on dialysis, timing of 
influenza vaccination, and valence. We observed differ-
ences between HDV and SDV in a few subgroups, but the 
patterns were not consistent across influenza seasons or age 
groups. Associations between a potential unmeasured 
confounder and our 3 outcomes would have required as-
sociations that are stronger than our measured 
confounder-outcome associations to have masked pre-
ventive effects.
Consideration of the results of comparative effective-
ness studies of preventive therapies requires careful 
thought about the tradeoffs of benefits versus costs. Due 
to the substantial influenza burden in the dialysis pop-
ulation, even small improvements in vaccine effective-
ness could be sufficient for recommending a specific type 
of annual influenza vaccination in this population. 
However, increased risks for side effects and increased 
costs must also be considered when weighing the cost-
benefit of implementing a new vaccination strategy. 
Our results suggest that the HDV does not provide 
additional benefit beyond the SDV on a population level. 
Additionally, the excess cost of the HDV is about $33 perdose,42 incurring an additional cost burden of $16.9
million under the assumption that all 511,000 patients
on dialysis would be vaccinated with HDV.43 HDV is also
more reactogenic, causing more frequent side effects,
although most of these adverse events are minor (eg,
injection-site reactions, systemic adverse events, and
gastrointestinal events).12,19,44-48 Safety data for the HDV
are limited to the healthy adult population; a comparison
of the safety of HDV versus SDV in patents receiving
dialysis is needed.
Previous observational studies have demonstrated that
SDVs are ineffective or minimally effective at reducing all-
cause mortality or influenza-related hospitalizations in
patients receiving dialysis29,49 despite reasonably robust
antibody responses regarded as protective in 30% to 90%
of vaccine recipients.50-55 Our work extends these findings
by clarifying that the HDV does not provide additional
protection beyond the SDV against all-cause mortality or
influenza-related outcomes, although the HDV elicits
greater antibody responses than SDV in patients receiving
dialysis.56 These observations highlight the importance of
postlicensure clinical studies that extend beyond
Subgroup Risk Difference, % (95% CI)SDV vs. HDV (N)
Age (years)
<65  0.49 (-0.76,  1.95)281,203 vs. 1,134
65-74  1.57 ( 0.43,  2.71)118,624 vs. 2,674
75-84 -1.62 (-2.89, -0.42)78,011 vs. 2,375
>=85 0.95 (-1.78,  3.38)22,804 vs. 727
Influenza season
2010/11  2.85 ( 0.59,  5.86)42,607 vs. 368
2011/12  1.05 (-0.62,  2.70)35,936 vs. 748
2012/13  0.36 (-1.31,  1.91)48,346 vs. 1,165
2013/14 -0.16 (-1.66,  1.54)44,413 vs. 1,447
2014/15 -0.52 (-1.66,  0.77)48,137 vs. 2,048
Years with ESRD
<1 year -1.79 (-4.51,  0.87)11,394 vs. 420
1-2 years -0.29 (-1.60,  0.91)76,237 vs. 2,512
3-4 years 1.65 (-0.40,  3.54)54,441 vs. 1,348
5-9 years -0.07 (-2.04,  1.70)58,560 vs. 1,172
>=10 years 0.75 (-2.47,  4.28)18,807 vs. 324
Timing of vaccination
August / September  0.35 (-0.72,  1.46)130,035 vs. 3,124
October or later -0.03 (-1.18,  1.39)89,404 vs. 2,652
Valence of SDV
Trivalent  0.33 (-0.54,  1.15)168,288 vs. 5,776
Quadrivalent -0.12 (-1.07,  0.89)51,151 vs. 5,776
-6 -4 -2 0 2 4 6
Figure 4. The risk for hospitalization due to influenza/pneumonia among patients who received the high-dose (HDV) versus
standard-dose (SDV) influenza vaccine, by subgroup. Risk differences were calculated as the difference between weighted cumu-
lative risk functions, accounting for the competing risk for death, with bootstrap confidence intervals (CIs). Analyses were performed
in adults 65 years and older, with the exception of the age-stratified analyses. Abbreviation: ESRD, end-stage renal disease.immunogenicity-related outcomes to incorporate clinical
outcomes.
Our conclusions differ somewhat from an observational
study using data from a not-for-profit dialysis provider in
the United States.21 Similar to our study, Miskulin et al21
reported similar rates of all-cause mortality among HDV
versus SDV recipients. In contrast to our study, Miskulin
et al reported lower rates of all-cause hospitalization
among HDV versus SDV recipients, though their finding
was restricted to the 2016 to 2017 influenza season and
not the 2015 to 2016 season. The 95% CIs for the pre-
ventive effect of HDV (hazard ratio, 0.93; 95% CI, 0.86-
1.00) included the null value, whereas the effect estimate
moved down and away from the null in the subgroup
analysis restricted to patients 65 years and older (hazard
ratio, 0.88; 95% CI, 0.79-0.97). Other stratified analyses
suggested similar protection among HDV and SDV
recipients.
Our results are not directly comparable with the
previous study given several differences. Specifically,
Miskulin et al included later seasons (2015/2016 and
2016/2017), patients undergoing peritoneal dialysis,
and a smaller sample size (N = 19,157). Furthermore,the previous study did not incorporate influenza-
related outcomes or use competing-risks methodology
to account for the high mortality in the dialysis
population.
Perhaps most importantly, the analysis by Miskulin et al
accounted for a limited set of potential confounders and
therefore their effect estimates may be subject to residual
confounding bias. In contrast, our study accounted for
potential confounding by frailty30,31 and the healthy-user
bias32,33 through adjustment for a comprehensive set of
individual- and facility-level potential confounders. It is
well established that observational studies of the effec-
tiveness of preventive interventions such as influenza
vaccination in elderly or sick populations can be highly
subject to confounding by frailty and health care–seeking
behavior because those who receive the treatment gener-
ally have higher anticipation of benefit by providers (eg,
longer predicted life expectancies) or stronger personal
motivation to receive care (eg, better access to health care,
higher socioeconomic status, and less frailty).49,57-60
Often, this confounding is difficult to control and results
in artificially protective adjusted effect estimates due to
residual confounding.
Subgroup Risk Difference, % (95% CI)SDV vs. HDV (N)
Age (years)
<65  2.15 (-0.29,  4.77)281,203 vs. 1,134
65-74  1.82 ( 0.05,  3.70)118,624 vs. 2,674
75-84 -2.40 (-4.17, -0.23)78,011 vs. 2,375
>=85 1.39 (-2.69,  4.98)22,804 vs. 727
Influenza season
2010/11  4.91 ( 0.00,  9.81)42,607 vs. 368
2011/12  2.11 (-0.99,  4.74)35,936 vs. 748
2012/13  0.40 (-2.10,  3.22)48,346 vs. 1,165
2013/14 -1.26 (-3.47,  1.49)44,413 vs. 1,447
2014/15 -0.89 (-2.72,  0.85)48,137 vs. 2,048
Years with ESRD
<1 year  0.07 (-4.93,  5.29)11,394 vs. 420
1-2 years -0.74 (-2.89,  0.88)76,237 vs. 2,512
3-4 years 0.92 (-1.62,  3.42)54,441 vs. 1,348
5-9 years 67.00 (-2.34,  3.38)58,560 vs. 1,172
>=10 years -0.04 (-4.84,  5.40)18,807 vs. 324
Timing of vaccination
August / September  0.47 (-1.00,  2.26)130,035 vs. 3,124
October or later -0.34 (-2.32,  1.47)89,404 vs. 2,652
Valence of SDV
Trivalent  0.32 (-0.83,  1.37)168,288 vs. 5,776
Quadrivalent -1.02 (-2.80,  0.65)51,151 vs. 5,776
-6 -4 -2 0 2 4 6
Figure 5. The risk for influenza-like illness among patients who received the high-dose (HDV) versus standard-dose (SDV) influenza
vaccine, by subgroup. Risk differences were calculated as the difference between weighted cumulative risk functions, accounting for
the competing risk for death, with bootstrap confidence intervals (CIs). Analyses were performed in adults 65 years and older, with
the exception of the age-stratified analyses. Abbreviation: ESRD, end-stage renal disease.We were concerned that this phenomenon might also be 
present when comparing HDV, a newer, more expensive, 
specialized vaccine, to the SDV. However, that is not what 
we observed. Instead, older individuals receiving HDV 
tended to be sicker and the crude effect estimate was above 
the null, suggesting that the confounding was not due to the 
healthy-user phenomenon. This is supported by our previ-
ous work, in which we demonstrated that comparisons of 
HDV to SDV among adult patients receiving dialysis are less 
subject to confounding by the healthy-user bias than 
comparisons of vaccinated versus unvaccinated persons.61 
However, despite our attempts, the possibility of unmea-
sured confounding remains.
Our findings should be interpreted within the context 
of several factors that affect vaccine effectiveness, including 
influenza virus circulation, serologic vaccine match, and 
seasonal influenza severity.62 Our study period included a 
range of seasonal influenza severity (1 low severity, 2 
moderate, and 2 high seasons) as measured in the overall 
population of older adults in the United States.63 These 
severity metrics correlated with the observed seasonal risk 
for clinical outcomes in our analyses. Also, influenza A(H3N2) viruses, which are associated with lower vaccine
effectiveness, were the predominant strains during all
influenza seasons in our study, with the exception of 2013
to 2014.23-27 Compared to influenza A (H1N1) or influ-
enza B viruses, H3N2 viruses have more frequently un-
dergone antigenic change, resulting in differences between
the virus components of the influenza vaccine and circu-
lating influenza viruses.64 However, the serologic vaccine
match, the proportion of circulating influenza strains that
matched the vaccine, was relatively high during 3 of the 4
seasons with H3N2 as the predominant strain (ie, 97%,
80%, 86%, and 40% for seasons 2010/2011, 2011/2012,
2012/2013, and 2014/2015, respectively),23-27 indi-
cating similarity between the influenza viruses in the
vaccine and circulating in the community.
Our results are subject to several limitations. First, our
observational study design did not involve randomization
of the exposure and therefore our effect estimates are
potentially subject to confounding by unobserved differ-
ences between exposure groups. However, we attempted
to control confounding through restriction of the study
population (ie, by vaccination status and age), as well as
analytic adjustment for a rich set of covariates. It is note-
worthy that we did not account for individual dialysis
facilities within our regression models; however, our
analysis accounted for dialysis center–level characteristics,
several of which were strong predictors of HDV receipt.11
Second, our analysis only accounted for baseline char-
acteristics measured before vaccination. However, this
approach is supported by a previous study of influenza
vaccine effectiveness among patients receiving hemodial-
ysis that demonstrated that accounting for time-varying
confounders of health status measured from both clinical
and claims data did not reduce bias.49
Third, our study design required survival until 9
months after dialysis initiation; therefore, our results may
not generalize to all incident patients. Fourth, in the
absence of laboratory-confirmed influenza outcomes, we
used claims-based definitions. Thus, outcome misclassifi-
cation is a possibility, though we used sensitivity analyses
to explore the impact of the definitions on our findings.
Fifth, some subgroup analyses may have had limited ability
to detect a true difference between HDV and SDV given
small numbers of HDV recipients. Sixth, the start date of
follow-up was based on national influenza data and
therefore ignores geographic variation in the timing of
influenza seasons.
Last, our study is primarily based on administrative
billing claims data, which are collected for administrative
and reimbursement purposes, rather than for clinical
research. Thus, we were not able to account for certain
important clinical factors unavailable in claims data (eg,
body mass index, vascular access, and laboratory mea-
surements) that may result in confounding bias, and some
of our measures may be subject to misclassification, such
as vaccination ascertainment if patients paid out of pocket.
However, we expect this misclassification to be unlikely
because patients receiving regular in-center hemodialysis
have very frequent health care encounters in dialysis
clinics, and influenza vaccination is offered to Medicare
beneficiaries without a co-pay. Importantly, our use of
these data is also a strength because it captures information
on a wide variety of health-related diagnoses, procedures,
use of durable medical equipment, frailty markers, hos-
pitalizations, and death.
In summary, our large comparative study failed to
demonstrate that HDV has superior effectiveness compared
to SDV for preventing all-cause mortality and influenza-
related outcomes among patients receiving maintenance
hemodialysis. Given the findings of our population-level
study, along with the substantially higher cost and side-
effect profile of HDV compared to SDV, it appears that
HDV should not conclusively be considered the standard of
care at the present time for influenza immunization of
patients treated by maintenance hemodialysis. The findings
of our population-level study should not be interpreted to
discourage influenza vaccination in the dialysis population.
Rather, dialysis patients should continue to receive annual
influenza immunization per CDC guidelines.8 In addition,future studies of alternative strategies (eg, booster doses)
and alternative vaccine production technologies (eg,
adjuvanted or cell-based vaccines) are warranted because
there remains a need for improved influenza prevention
efforts in this population.Supplementary Material
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